Corvus Pharmaceuticals (CRVS) Stock Forecast & Price Target

CRVS$10.60-0.04 -0.38%
BiotechnologyValue StockGrowth Stock
Compare
Market cap$894.14MEnterprise value$872.25MRevenue (TTM)$0Market position—

Score

70
Bullish
Value
62
Quality
47
Growth
100

Corvus Pharmaceuticals, Inc. price target

CRVS
Low$27.00
Average$27.00
High$27.00
Upside vs current price+154.7%

The average target of $27.00 is +154.7% versus the current CRVS price of $10.60.

Corvus Pharmaceuticals, Inc. analyst ratings

RatingAnalysts
Strong buy1
Buy6
Hold0
Sell0
Strong sell0
ConsensusBuy

7 analysts cover CRVS.

Corvus Pharmaceuticals, Inc. EPS and revenue estimates

CRVS shows the next fiscal years with at least three analysts: 2026 EPS $-0.75, 2027 EPS $-0.94. A thinner year is left off this table.

Fiscal yearEPS estimateRevenue estimate
2026$-0.75$1.18M
2027$-0.94$4.55M

Is Corvus Pharmaceuticals, Inc. a buy or sell?

Of the 7 analysts covering Corvus Pharmaceuticals, Inc., 7 rate it a buy (1 strong buy and 6 buy), 0 rate it a hold, and 0 rate it a sell (0 sell and 0 strong sell).

The CRVS consensus label is Buy, beside 7 buy-side ratings and 0 sell-side ratings.

The average target of $27.00 implies +154.7% versus the current price of $10.60.

Those 7 ratings on CRVS are a headcount, and the label on file is Buy.

Reading the Corvus Pharmaceuticals, Inc. forecast

The CRVS targets sit in a narrow band, from $27.00 to $27.00, around an average of $27.00.

Set next to the $10.60 CRVS quote, that average is +154.7%.

Ratings on the Corvus Pharmaceuticals, Inc. cluster: 7 of 7 analysts are on the buy side, 0 are at hold, and 0 are on the sell side, and the published consensus is Buy.

The CRVS average target is little changed, $27.00 over the last month and $27.00 over the last quarter.

Only 7 analysts cover CRVS, so the average rests on a short list.

Corvus Pharmaceuticals, Inc. forecast questions

What is the CRVS price target?

The published range for CRVS is $27.00 to $27.00, with an average of $27.00. That average is +154.7% versus the current price of $10.60.

Is Corvus Pharmaceuticals, Inc. a buy or sell?

Of the 7 analysts covering Corvus Pharmaceuticals, Inc., 7 rate it a buy, 0 rate it a hold, and 0 rate it a sell. The consensus is Buy, and the CRVS headcount is 7 buy, 0 hold, and 0 sell.

What is the EPS estimate for Corvus Pharmaceuticals, Inc.?

Analyst EPS estimates for Corvus Pharmaceuticals, Inc.: 2026 $-0.75, 2027 $-0.94.

What is the revenue estimate for Corvus Pharmaceuticals, Inc.?

Analyst revenue estimates for Corvus Pharmaceuticals, Inc.: 2026 $1.18M, 2027 $4.55M.

How many analysts cover CRVS?

7 analysts cover CRVS. Their consensus on CRVS is Buy, across those 7.

CRVS price $10.60 -0.04 -0.38%

Insights · Forecast · Financials · Learn

Stocklytics home · Screener